Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de CDPATH™ para ayudar a controlar y tratar la enfermedad de Crohn (COMPASS-CD)

5 de octubre de 2026 actualizado por: Takeda

Un estudio de fase 4 que evalúa el uso en el mundo real de CDPATH™, una herramienta de predicción del riesgo de la enfermedad de Crohn

CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

The tool being tested in this study is called CDPATH™. CDPATH™ is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH™.

The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH™ process and with their treatment choice.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.

Tipo de estudio

Intervencionista

Inscripción (Actual)

241

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85032
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Loma Linda, California, Estados Unidos, 92357
        • VA Loma Linda Healthcare System
      • Murrieta, California, Estados Unidos, 92563
        • United Medical Doctors
      • Newport Beach, California, Estados Unidos, 92663
        • University of Southern California Medical Center
      • Orange, California, Estados Unidos, 92868
        • University of California at Irvine Medical Center
      • Orange, California, Estados Unidos, 92868
        • Clinnova Research Solutions
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80014
        • Kaiser Permanate of Colorado
    • Connecticut
      • Hamden, Connecticut, Estados Unidos, 06518
        • Medical Research Center of Connecticut, LLC
    • Florida
      • Clearwater, Florida, Estados Unidos, 33762
        • West Central Gastroenterology d/b/a Gastro Florida
      • Pensacola, Florida, Estados Unidos, 32503
        • Gastroenterology Associates of Pensacola, PA
    • Idaho
      • Idaho Falls, Idaho, Estados Unidos, 83404
        • Grand Teton Research Group, PLL
    • Illinois
      • Arlington Heights, Illinois, Estados Unidos, 60005
        • GI Alliance
      • Gurnee, Illinois, Estados Unidos, 60031
        • GI Alliance
      • Northbrook, Illinois, Estados Unidos, 60062
        • Comprehensive Gastrointestinal Health
      • Rockford, Illinois, Estados Unidos, 61107
        • Rockford Gastroenterology Associates, Ltd.
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Indiana University
    • Iowa
      • Clive, Iowa, Estados Unidos, 50325
        • Iowa Digestive Disease Center
      • Iowa City, Iowa, Estados Unidos, 52242-1009
        • University of Iowa Hospitals & Clinics
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • University of Kansas Medical Center Research Institute, Inc.
    • Louisiana
      • Baton Rouge, Louisiana, Estados Unidos, 70809
        • GI Alliance - Baton Rouge
      • Shreveport, Louisiana, Estados Unidos, 71105
        • Louisiana Research Center, LLC
    • Maryland
      • Columbia, Maryland, Estados Unidos, 21045
        • Gastro Center of Maryland
    • Massachusetts
      • Burlington, Massachusetts, Estados Unidos, 01805
        • Lahey Clinic Inc. - PARENT ACCOUNT
      • Worcester, Massachusetts, Estados Unidos, 01655
        • UMASS Memorial Medical Center
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87131-0001
        • University of New Mexico
    • New York
      • New York, New York, Estados Unidos, 10075-1850
        • Lenox Hill Hospital
    • Ohio
      • Beavercreek, Ohio, Estados Unidos, 45431
        • Clinical Inquest Center Ltd
      • Dayton, Ohio, Estados Unidos, 45415
        • Dayton Gastroenterology, Inc
    • Oregon
      • Portland, Oregon, Estados Unidos, 97220-9442
        • The Oregon Clinic, P.C.
    • Pennsylvania
      • Camp Hill, Pennsylvania, Estados Unidos, 17011
        • Susquehanna Research Group, LLC
      • Pittsburgh, Pennsylvania, Estados Unidos, 15213
        • University of Pittsburgh Medical Center Health System
      • Pittsburgh, Pennsylvania, Estados Unidos, 15212
        • Allegheny Center for Digestive Health
      • Uniontown, Pennsylvania, Estados Unidos, 15401
        • Frontier Clinical Research, LLC
    • South Carolina
      • Summerville, South Carolina, Estados Unidos, 29486
        • Palmetto Primary Care Physician Division of Gastroenterology
    • South Dakota
      • Rapid City, South Dakota, Estados Unidos, 57701
        • Rapid City Medical Center, LLC
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37204
        • Vanderbilt University Medical Center
    • Texas
      • Austin, Texas, Estados Unidos, 78712
        • The University of Texas at Austin
      • Houston, Texas, Estados Unidos, 77030
        • Baylor College of Medicine
      • Southlake, Texas, Estados Unidos, 76092
        • GI Alliance - Southlake
    • Utah
      • Ogden, Utah, Estados Unidos, 84403
        • Care Access Research Berkley
      • Salt Lake City, Utah, Estados Unidos, 84132
        • University of Utah
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • GCGA Physicians LLC
      • Lynchburg, Virginia, Estados Unidos, 24502
        • Gastroenterology Associates
    • Washington
      • Bellevue, Washington, Estados Unidos, 98405
        • GI Alliance

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
  2. Has agreed to use the CDPATH™ tool.
  3. Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.

Exclusion Criteria:

  1. Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
  2. Has had any non-CD-related abdominal surgery.
  3. Has received investigational biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
  4. Has previously used CDPATH™ or PROSPECT results to assess CD risk for complications.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Diagnóstico
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: CDPATH™

Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis.

Crohn's disease risk prediction tool.

Otros nombres:
  • PROSPECTO

Three blood samples will be drawn.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants in Real-world Practice in Each Risk Category at Baseline Based on the CDPATH™ Tool Results
Periodo de tiempo: Baseline (Day 1)

The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years.

Baseline (Day 1)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants with Specific Treatment Path and Choice Based on CDPATH™ Tool, Stratified According to Risk Category
Periodo de tiempo: Up to 36 months

Treatment path (i.e., sequence over time) and choice, by low, medium and high risk, will be chosen to characterize treatment path and choice based on risk stratification.

Up to 36 months
Change From Baseline in Decisional Conflict Scale (DCS) Score
Periodo de tiempo: Baseline, then every 6 months up to 36 months

DCS is a validated electronic patient-reported outcome (ePRO) collected via electronically administered patient surveys. It measures personal perceptions of the following responses: uncertainty in choosing options, modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making, and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. DCS involves answering 11 questions of PRO, of which 10 questions can be answered as yes (score = 0) or unsure (score = 2) or no (score =4). The total score will range from 0 to 40. Higher score indicates higher decisional conflict.

Baseline, then every 6 months up to 36 months
Change From Baseline in Work Productivity and Activity Impairment Questionnaire - CD Version (WPAI-CD) Score
Periodo de tiempo: Baseline, then every 6 months up to 36 months

WPAI-CD is a validated ePRO collected via electronically administered patient surveys. It consists of six questions that evaluate 4 domain scores: absenteeism (i.e., work time missed), presenteeism (i.e., reduced work productivity), overall work impairment, and activity impairment. Scores are expressed as a percentage of impairment, where higher scores indicate greater impairment and reduced productivity. The total score ranges from 0 (no impairment) to 100% (total loss of work productivity).

Baseline, then every 6 months up to 36 months
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale Score
Periodo de tiempo: Baseline, then every 6 months up to 36 months

PROMIS Global Health scale is a validated ePRO collected via electronically administered patient surveys. It is a 10-item PRO measuring the overall evaluation of one's physical and mental health. The total score ranges from 0 to 100. The final score will be represented by the T-score metric, in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A higher PROMIS T-score represents more of the concept being measured (higher Global Health score indicate better health).

Baseline, then every 6 months up to 36 months
Patient-Reported Satisfaction and Experience Score with the CDPATH™ Tool
Periodo de tiempo: Up to 36 months

Participant's satisfaction and experience with the CDPATH™ tool will be assessed based on 15 questions. Negative responses/lower score to/in these questions indicates less satisfaction whereas positive responses/higher score indicates satisfaction with the tool.

Up to 36 months
Number of Participants with Clinical Outcomes
Periodo de tiempo: Up to 36 months

Participants with clinical outcomes describing the disease burden based on treatment path and controlling for risk strata will be reported.

Up to 36 months
Percentage of Participants with Healthcare Resource Utilization
Periodo de tiempo: Up to 36 months

Healthcare resource includes healthcare provider (HCP) visits/referrals, visit to emergency room, hospitalizations, surgery, new CD-related complications, and diagnostic evaluations (e.g., imaging, colonoscopy, etc.).

Up to 36 months
Change from First Assessment in Health Care Provider (HCP)-reported Assessment of the Feasibility and Usability of the CDPATH™ Tool
Periodo de tiempo: First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

HCP-reported CDPATH™ satisfaction data will be collected directly from HCPs via electronically administered HCP surveys and entered into the eCRF. HCPs will be queried regarding their satisfaction and experience with the general process, the ease of incorporating the tool in their everyday practice, and the impact of the tool on their treatment recommendations and participant communications. For the 6 questions, HCP will rate on 1-5 scale where, 1=strongly disagree and 5=strongly agree. For remaining 4 questions, written feedback from HCP will be consider. Overall positive responses will indicate higher feasibility and usability.

First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Study Director, Takeda

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

25 de junio de 2021

Finalización primaria (Actual)

27 de agosto de 2026

Finalización del estudio (Actual)

27 de agosto de 2026

Fechas de registro del estudio

Enviado por primera vez

19 de marzo de 2021

Primero enviado que cumplió con los criterios de control de calidad

19 de marzo de 2021

Publicado por primera vez (Actual)

22 de marzo de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

8 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • Vedolizumab-4015

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Criterios de acceso compartido de IPD

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .